Freezing out tumors: could cryoablation replace surgery for early breast cancer?
NCT ID NCT07447414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether freezing early-stage breast cancer tumors (cryoablation) can safely and effectively destroy them in postmenopausal women. Participants will have the frozen tumor removed afterward to check for any remaining cancer cells. The goal is to see if this less invasive approach could be an alternative to standard surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 140 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Postmenopausal women diagnosed with invasive breast cancer by core needle biopsy or vacuum-assisted biopsy * Unifocal * Lesion ≤ 2 cm (on ultrasound and contrast enhanced mammography) * No axillary lymphadenopathy on ultrasound * No axillary lymph node involvement on ultrasound. * Luminal tumor (estrogen and/or progesterone receptor positive) * HER2 negative * Signed informed consent Exclusion Criteria: * Infiltrating lobular carcinoma * Extensive in situ component * Multifocality or multicentricity * Contraindication for contrast mammography * Not candidate for surgery * Distant metastasis -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Universitario Lucus Augusti
RECRUITINGLugo, Lugo, 27003, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?